Plasma Homocysteine Is Not Involved in the Thrombotic Risk of β-Thalassemia major Patients

Barrano, Barbara; Bertrand, Giuliano; Isaja, Teresa; Curreri, R; Musumeci, Salvatore

doi:10.1159/000039752

Cited by 9 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In concurrence with previous studies [17,22], we found a marked increase in serum ferritin concentrations in thalassaemic patients. The increment in lowmolecular weight iron in serum and in the intracellular transit pool of iron due to continuous blood transfusions promotes peroxidative damage in thalassaemic patients [17,18].…”

Section: Discussionsupporting

confidence: 93%

“…One-third (34.3 %) of [22]. These authors did their study in 65 Sardinian ß-thalassaemia major patients with an absolute prevalence (95.7 %) of the codon ß 39 nonsense mutation and they used the fluorescence polarization immunoassay method to determine plasma HCY levels.…”

Section: Discussionmentioning

confidence: 99%

“…However, to our knowledge, the status of HCY in thalassaemic patients has not yet been adequately defined. The only study in the literature investigating the relation between HCY and thrombotic risk in thalassaemic patients, that by Barrano et al [22], concluded that there was no significant change in plasma HYC levels compared to control subjects. Since the possible alterations in plasma HCY levels may have serious potential consequences, the present study aimed to investigate the level of HCY and its relation with vitamin B12, folate and oxidative stress in thalassaemic patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma homocysteine levels in patients with β‐thalassaemia major

Özdem

Küpesiz²,

Yeşilipek

2008

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma homocysteine levels in patients with β‐thalassaemia major

Özdem

Küpesiz²,

Yeşilipek

2008

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

show abstract

“…This finding is similar to that of a study done by Barrano et al [7 ]which showed that their 65 Italian thalassemic patients had normal plasma homocysteine levels and concluded that there was no significant association between β-thalassemia major and hyperhomocysteinemia.…”

Section: Discussionsupporting

confidence: 92%

“…Congenital or acquired factors can contribute to this hypercoagulability. In some cases thromboembolic events in thalassemic patients occurred in association with acquired risk factors such as iron overload, diabetes, complex cardiopulmonary abnormalities, hypothyroidism, liver function anomalies and postsplenectomy thrombocytosis [7,8,9]. …”

Section: Introductionmentioning

confidence: 99%

Hypercoagulable State and Methylenetetra- hydrofolate Reductase (MTHFR) C677T Mutation in Patients with Beta-Thalassemia Major in Kuwait

Mustafa

Marouf²,

Al-Humood³

et al. 2009

Acta Haematol

View full text Add to dashboard Cite

Introduction: Patients with thalassemia major often present with a hypercoagulable state, the pathogenesis of which is still not understood. Materials and Methods: This study evaluates the risk factors for hypercoagulability in 50 β-thalassemia major patients and 50 healthy controls. Fasting total homocysteine, protein C (PC), protein S (PS), antithrombin (AT), activated protein C resistance (APCR) and lupus anticoagulant (LA) were assessed. MTHFR C677T mutation was determined. Results: Significant reductions in PC, PS and AT were noted in patients. Only 4% of the patients had hyperhomocysteinemia. Thirty-two percent of the patients were heterozygous and 4% were homozygous for MTHFR C677T mutation. Conclusion: The natural coagulation inhibitors PC, PS and AT were significantly reduced in patients with β-thalassemia major and were thus important risk factors for the hypercoagulable state, but hyperhomocysteinemia and MTHFR mutation do not seem to be significant risk factors for thromboembolic events.

show abstract